BIMINI Biotech

Targeting the growth hormone receptor (GHR) for the treatment of cancer

BIMINI Biotech is an innovative spin-off from the University Medical Center Utrecht (UMCU), which aims to target the growth hormone receptor (GHR) for the treatment of cancer. Our innovative approach is based on years of prominent research conducted at UMCU by Prof. dr. Ger Strous. We have identified and patented a lead compound for the treatment of triple negative breast cancer (TNBC), a growing disease segment with a huge clinical and market need, as our first showcase. Our lead compound has shown highly promising in vitro, in vivo and toxicity results, inhibiting TNBC in mice. We now aim to further the pre-clinical and clinical development of this compound, steering towards a lucrative licensing deal. Our team consists of a mix of young entrepreneurs, experienced business experts, and renowned scientific key-opinion-leaders – with a demonstrated track-record in bringing companies to a successful exit. At BIMINI we have a combined desire to increase the duration and quality of human life.

Maurits van den Nieuwboer
Digvijay Gahtory
Ger Strous
Startup activities

Winner Venture Challenge Fall 2019

Maurits van den Nieuwboer